Our Science
Our Advantage
Our Performance
Our Publications
About Us
Leadership
Advisors
Board and Investors
Our History
News & Press
Partnerships
Contact Us
Join Us
Our Science
Our Advantage
Our Performance
Our Publications
About Us
Leadership
Advisors
Board and Investors
Our History
News & Press
Partnerships
Contact Us
Join Us
Culture
Benefits
Values
Job Openings
News & Press
follow us
into the future
Our platform, which combines oncRNA technology with AI, provides actionable insights into cancer biology.
Featured
Exai Bio Announces Publication in Nature Communications Highlighting its Generative AI Liquid Biopsy Platform
Read More >
Exai Bio Announces Publication in Nature Communications Highlighting its Generative AI Liquid Biopsy Platform
Nov 2024
Exai Bio Appoints Dave Daly as Chief Executive Officer
Jul 2024
Exai Bio to Present New Breast Cancer Data at the American Association for Cancer Research (AACR) 2024 Annual Meeting
Apr 2024
Exai Bio’s RNA- and AI-based Liquid Biopsy Platform Detects Early Stage Breast Cancer with High Accuracy, Overcoming Many Limitations of DNA-based Approaches
Dec 2023
Exai Bio Presents Data Further Validating its Liquid Biopsy Platform at the 2023 World Conference on Lung Cancer
Sep 2023
Exai Bio Presents New Multi-Cancer Early Detection Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Jun 2023
Exai Bio Presents New Non-Small Cell Lung Cancer Early Detection Data at the American Association for Cancer Research (AACR) 2023 Annual Meeting
Apr 2023
Exai Bio and Quantum Leap Healthcare Collaborative Announce Expanded Participation in I-SPY 2 Trial to Advance Exai’s Novel RNA-based Liquid Biopsy Platform in Breast Cancer
Mar 2023
Exai Bio Announces Appointments of Emi Zychlinsky and Seema Singh Bhan to its Executive Leadership Team
Feb 2023
Exai Bio’s RNA-based Liquid Biopsy Platform Delivers Promising Data on Detecting Breast Cancer at its Earliest Stages
Dec 2022
Exai Bio Presents Data Demonstrating that its Novel RNA-based Liquid Biopsy Platform has Potential for Early Detection and Monitoring of Colorectal Cancer
Sep 2022
Exai Bio Demonstrates its Unique RNA-based Liquid Biopsy Strategy for Early Detection and Monitoring of Multiple Cancers
Apr 2022
Exai Bio Secures $67.5 Million Series A
Dec 2021
stay up-to-date
Thank you for your interest!
Oops! Something went wrong. Please try again later.
Close the cookie popup
Cookie Settings
By clicking "Accept All", you are agreeing to store cookies on your device to enhance your experience and help Exai's marketing.
Accept All
cookie settings
Close the cookie popup
Cookie Settings
By clicking "Accept All", you are agreeing to store cookies on your device to enhance your experience and help Exai's marketing.
More info
.
Strictly Necessary
Required in order to enable all basic site functionality.
Personalization
Allows the site to remember choices that you make.
Analytics
Helps Exai better understand how the site performs.
Marketing
Used to deliver advertising that's more relevant to you.
Accept All
save settings